Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 61 to 65 of 65 entries
Sorted by: Best Match Show Resources per page
Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population.

Frontiers in immunology

Cyprian FS, Suleman M, Abdelhafez I, Doudin A, Masud Danjuma M, Mir FA, Parray A, Yousaf Z, Siddiqui MYA, Abdelmajid A, Mulhim M, Al-Shokri S, Abukhattab M, Shaheen R, Elkord E, Al-Khal AL, Elzouki AN, Girardi G.
PMID: 34966381
Front Immunol. 2021 Dec 13;12:707159. doi: 10.3389/fimmu.2021.707159. eCollection 2021.

Coronavirus disease-2019 (COVID-19) was declared as a pandemic by WHO in March 2020. SARS-CoV-2 causes a wide range of illness from asymptomatic to life-threatening. There is an essential need to identify biomarkers to predict disease severity and mortality during...

Cite
Cyprian FS, Suleman M, Abdelhafez I, et al. Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population. Front Immunol. 2021;12:707159doi: 10.3389/fimmu.2021.707159.
Cyprian, F. S., Suleman, M., Abdelhafez, I., Doudin, A., Masud Danjuma, M., Mir, F. A., Parray, A., Yousaf, Z., Siddiqui, M. Y. A., Abdelmajid, A., Mulhim, M., Al-Shokri, S., Abukhattab, M., Shaheen, R., Elkord, E., Al-Khal, A. L., Elzouki, A. N., & Girardi, G. (2021). Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population. Frontiers in immunology, 12707159. https://doi.org/10.3389/fimmu.2021.707159
Cyprian, Farhan S, et al. "Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population." Frontiers in immunology vol. 12 (2021): 707159. doi: https://doi.org/10.3389/fimmu.2021.707159
Cyprian FS, Suleman M, Abdelhafez I, Doudin A, Masud Danjuma M, Mir FA, Parray A, Yousaf Z, Siddiqui MYA, Abdelmajid A, Mulhim M, Al-Shokri S, Abukhattab M, Shaheen R, Elkord E, Al-Khal AL, Elzouki AN, Girardi G. Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population. Front Immunol. 2021 Dec 13;12:707159. doi: 10.3389/fimmu.2021.707159. eCollection 2021. PMID: 34966381; PMCID: PMC8710484.
Copy Download .nbib Format: NLM
C5 Variant rs10985126 is Associated with Mortality in Patients with Symptomatic Coronary Artery Disease.

Pharmacogenomics and personalized medicine

Henes JK, Groga-Bada P, Schaeffeler E, Winter S, Hack L, Zdanyte M, Mueller K, Droppa M, Stimpfle F, Gawaz M, Langer H, Schwab M, Geisler T, Rath D.
PMID: 34321906
Pharmgenomics Pers Med. 2021 Jul 21;14:893-903. doi: 10.2147/PGPM.S307827. eCollection 2021.

BACKGROUND: Complement component 5a (C5a) is a highly potent anaphylatoxin with a variety of pro-inflammatory effects. C5a contributes to progression of atherosclerosis and inhibition of the receptor (C5aR) might offer a therapeutic strategy in this regard. Single nucleotide polymorphisms...

Cite
Henes JK, Groga-Bada P, Schaeffeler E, et al. C5 Variant rs10985126 is Associated with Mortality in Patients with Symptomatic Coronary Artery Disease. Pharmgenomics Pers Med. 2021;14:893-903doi: 10.2147/PGPM.S307827.
Henes, J. K., Groga-Bada, P., Schaeffeler, E., Winter, S., Hack, L., Zdanyte, M., Mueller, K., Droppa, M., Stimpfle, F., Gawaz, M., Langer, H., Schwab, M., Geisler, T., & Rath, D. (2021). C5 Variant rs10985126 is Associated with Mortality in Patients with Symptomatic Coronary Artery Disease. Pharmacogenomics and personalized medicine, 14893-903. https://doi.org/10.2147/PGPM.S307827
Henes, Jessica Kristin, et al. "C5 Variant rs10985126 is Associated with Mortality in Patients with Symptomatic Coronary Artery Disease." Pharmacogenomics and personalized medicine vol. 14 (2021): 893-903. doi: https://doi.org/10.2147/PGPM.S307827
Henes JK, Groga-Bada P, Schaeffeler E, Winter S, Hack L, Zdanyte M, Mueller K, Droppa M, Stimpfle F, Gawaz M, Langer H, Schwab M, Geisler T, Rath D. C5 Variant rs10985126 is Associated with Mortality in Patients with Symptomatic Coronary Artery Disease. Pharmgenomics Pers Med. 2021 Jul 21;14:893-903. doi: 10.2147/PGPM.S307827. eCollection 2021. PMID: 34321906; PMCID: PMC8312322.
Copy Download .nbib Format: NLM
Genetic alterations in gastric amphicrine carcinomas and comparison with gastric mixed neuroendocrine-non-neuroendocrine neoplasms.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Sun L, Wang C, Zhang J, Shao B, Zhao S, Guo Y, Li X, Sun Y.
PMID: 34839352
Mod Pathol. 2021 Nov 27; doi: 10.1038/s41379-021-00978-5. Epub 2021 Nov 27.

Gastric amphicrine carcinoma, in which endocrine and epithelial cell features are present within the same cells, is often confused with gastric mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN). In this study, we performed high-resolution copy number (CN) profiling and whole exome sequencing...

Cite
Sun L, Wang C, Zhang J, et al. Genetic alterations in gastric amphicrine carcinomas and comparison with gastric mixed neuroendocrine-non-neuroendocrine neoplasms. Mod Pathol. 2021;doi: 10.1038/s41379-021-00978-5.
Sun, L., Wang, C., Zhang, J., Shao, B., Zhao, S., Guo, Y., Li, X., & Sun, Y. (2021). Genetic alterations in gastric amphicrine carcinomas and comparison with gastric mixed neuroendocrine-non-neuroendocrine neoplasms. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, . https://doi.org/10.1038/s41379-021-00978-5
Sun, Lin, et al. "Genetic alterations in gastric amphicrine carcinomas and comparison with gastric mixed neuroendocrine-non-neuroendocrine neoplasms." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc vol. (2021). doi: https://doi.org/10.1038/s41379-021-00978-5
Sun L, Wang C, Zhang J, Shao B, Zhao S, Guo Y, Li X, Sun Y. Genetic alterations in gastric amphicrine carcinomas and comparison with gastric mixed neuroendocrine-non-neuroendocrine neoplasms. Mod Pathol. 2021 Nov 27; doi: 10.1038/s41379-021-00978-5. Epub 2021 Nov 27. PMID: 34839352.
Copy Download .nbib Format: NLM
Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis.

Cancer letters

Ortiz-Espinosa S, Morales X, Senent Y, Alignani D, Tavira B, Macaya I, Ruiz B, Moreno H, Remírez A, Sainz C, Rodriguez-Pena A, Oyarbide A, Ariz M, Andueza MP, Valencia K, Teijeira A, Hoehlig K, Vater A, Rolfe B, Woodruff TM, Lopez-Picazo JM, Vicent S, Kochan G, Escors D, Gil-Bazo I, Perez-Gracia JL, Montuenga LM, Lambris JD, Ortiz de Solorzano C, Lecanda F, Ajona D, Pio R.
PMID: 34971753
Cancer Lett. 2021 Dec 28;529:70-84. doi: 10.1016/j.canlet.2021.12.027. Epub 2021 Dec 28.

Myeloid-derived suppressor cells (MDSCs) play a major role in cancer progression. In this study, we investigated the mechanisms by which complement C5a increases the capacity of polymorphonuclear MDSCs (PMN-MDSCs) to promote tumor growth and metastatic spread. Stimulation of PMN-MDSCs...

Cite
Ortiz-Espinosa S, Morales X, Senent Y, et al. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. Cancer Lett. 2021;529:70-84doi: 10.1016/j.canlet.2021.12.027.
Ortiz-Espinosa, S., Morales, X., Senent, Y., Alignani, D., Tavira, B., Macaya, I., Ruiz, B., Moreno, H., Remírez, A., Sainz, C., Rodriguez-Pena, A., Oyarbide, A., Ariz, M., Andueza, M. P., Valencia, K., Teijeira, A., Hoehlig, K., Vater, A., Rolfe, B., Woodruff, T. M., Lopez-Picazo, J. M., Vicent, S., Kochan, G., Escors, D., Gil-Bazo, I., Perez-Gracia, J. L., Montuenga, L. M., Lambris, J. D., Ortiz de Solorzano, C., Lecanda, F., Ajona, D., & Pio, R. (2021). Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. Cancer letters, 52970-84. https://doi.org/10.1016/j.canlet.2021.12.027
Ortiz-Espinosa, Sergio, et al. "Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis." Cancer letters vol. 529 (2021): 70-84. doi: https://doi.org/10.1016/j.canlet.2021.12.027
Ortiz-Espinosa S, Morales X, Senent Y, Alignani D, Tavira B, Macaya I, Ruiz B, Moreno H, Remírez A, Sainz C, Rodriguez-Pena A, Oyarbide A, Ariz M, Andueza MP, Valencia K, Teijeira A, Hoehlig K, Vater A, Rolfe B, Woodruff TM, Lopez-Picazo JM, Vicent S, Kochan G, Escors D, Gil-Bazo I, Perez-Gracia JL, Montuenga LM, Lambris JD, Ortiz de Solorzano C, Lecanda F, Ajona D, Pio R. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. Cancer Lett. 2021 Dec 28;529:70-84. doi: 10.1016/j.canlet.2021.12.027. Epub 2021 Dec 28. PMID: 34971753.
Copy Download .nbib Format: NLM
Anaphylatoxin receptor promiscuity for commonly used complement C5a peptide agonists.

International immunopharmacology

Li XX, Clark RJ, Woodruff TM.
PMID: 34454293
Int Immunopharmacol. 2021 Nov;100:108074. doi: 10.1016/j.intimp.2021.108074. Epub 2021 Aug 25.

The complement system is an essential component of innate immunity. Its activation generates the effector cleavage proteins, anaphylatoxins C3a and C5a, that exert activity by interacting with three structurally related seven-transmembrane receptors. C3a activates C3aR, whilst C5a interacts with...

Cite
Li XX, Clark RJ, Woodruff TM. Anaphylatoxin receptor promiscuity for commonly used complement C5a peptide agonists. Int Immunopharmacol. 2021;100:108074doi: 10.1016/j.intimp.2021.108074.
Li, X. X., Clark, R. J., & Woodruff, T. M. (2021). Anaphylatoxin receptor promiscuity for commonly used complement C5a peptide agonists. International immunopharmacology, 100108074. https://doi.org/10.1016/j.intimp.2021.108074
Li, Xaria X, et al. "Anaphylatoxin receptor promiscuity for commonly used complement C5a peptide agonists." International immunopharmacology vol. 100 (2021): 108074. doi: https://doi.org/10.1016/j.intimp.2021.108074
Li XX, Clark RJ, Woodruff TM. Anaphylatoxin receptor promiscuity for commonly used complement C5a peptide agonists. Int Immunopharmacol. 2021 Nov;100:108074. doi: 10.1016/j.intimp.2021.108074. Epub 2021 Aug 25. PMID: 34454293.
Copy Download .nbib Format: NLM
Showing 61 to 65 of 65 entries